ARTICLE | Company News
Therion other research news
January 30, 1995 8:00 AM UTC
Three articles in the New England Journal of Medicine provide support for Cambridge, Mass.-based Therion's efforts to develop a live AIDS vaccine attenuated by deletion of the nef gene and several other genes.
One paper reported on a single patient with long-term HIV infection who shows no signs of illness and appears to have been infected with a mutant form of HIV missing the nef gene. The patient also appears to be resistant to infection by normal HIV. ...